- Home
- SBLK vs IMCR Comparison
SBLK vs IMCR Comparison
Compare SBLK & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBLK
- IMCR
- Stock Information
- Founded
- SBLK 2006
- IMCR 2008
- Country
- SBLK Greece
- IMCR United Kingdom
- Employees
- SBLK N/A
- IMCR N/A
- Industry
- SBLK Marine Transportation
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SBLK Consumer Discretionary
- IMCR Health Care
- Exchange
- SBLK Nasdaq
- IMCR Nasdaq
- Market Cap
- SBLK 1.8B
- IMCR 1.4B
- IPO Year
- SBLK N/A
- IMCR 2021
- Fundamental
- Price
- SBLK $16.49
- IMCR $28.62
- Analyst Decision
- SBLK Strong Buy
- IMCR Buy
- Analyst Count
- SBLK 3
- IMCR 12
- Target Price
- SBLK $22.67
- IMCR $63.00
- AVG Volume (30 Days)
- SBLK 3.0M
- IMCR 238.4K
- Earning Date
- SBLK 02-18-2025
- IMCR 05-07-2025
- Dividend Yield
- SBLK 12.96%
- IMCR N/A
- EPS Growth
- SBLK 60.00
- IMCR N/A
- EPS
- SBLK 2.80
- IMCR N/A
- Revenue
- SBLK $1,265,458,000.00
- IMCR $310,202,000.00
- Revenue This Year
- SBLK N/A
- IMCR $18.97
- Revenue Next Year
- SBLK $18.23
- IMCR $8.43
- P/E Ratio
- SBLK $5.64
- IMCR N/A
- Revenue Growth
- SBLK 33.31
- IMCR 24.37
- 52 Week Low
- SBLK $14.30
- IMCR $27.19
- 52 Week High
- SBLK $27.47
- IMCR $66.00
- Technical
- Relative Strength Index (RSI)
- SBLK 60.15
- IMCR 42.97
- Support Level
- SBLK $15.18
- IMCR $27.19
- Resistance Level
- SBLK $16.29
- IMCR $31.20
- Average True Range (ATR)
- SBLK 0.57
- IMCR 1.65
- MACD
- SBLK 0.07
- IMCR -0.09
- Stochastic Oscillator
- SBLK 92.82
- IMCR 31.29
About SBLK Star Bulk Carriers Corp.
Star Bulk Carriers Corp provides seaborne transportation solutions in the dry bulk sector. The company owns and operates dry bulk carrier vessels, which are used to transport bulk, such as iron ore, coal, grains, bauxite, fertilizers, and steel products. It owns a fleet of vessels that consists of Newcastlemax, Capesize, Post Panamax, Kamsarmax, Panamax, Ultramax, and Supramax. It generates revenues through the voyages it carries out.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.